Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gao, P.
Right arrow Articles by Hamaoka, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gao, P.
Right arrow Articles by Hamaoka, T.
(Journal of Leukocyte Biology. 2003;73:273-280.)
© 2003 by Society for Leukocyte Biology

The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3

Ping Gao*, Xu-Yu Zhou*, Yumi Yashiro-Ohtani*, Yi-Fu Yang*, Naotoshi Sugimoto*, Shiro Ono*, Tsuyoshi Nakanishi{dagger}, Satoshi Obika{ddagger}, Takeshi Imanishi{ddagger}, Takeshi Egawa§, Takashi Nagasawa§, Hiromi Fujiwara* and Toshiyuki Hamaoka*

* Departments of Oncology, Osaka University Graduate School of Medicine, and
{dagger} Toxicology and
{ddagger} Bioorganic Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Japan; and
§ Department of Immunology, Research Institute, Osaka Medical Center for Maternal and Child Health, Japan

Correspondence: Dr. Hiromi Fujiwara, Department of Oncology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka 565-0871, Japan. E-mail: hf{at}ongene.med.osaka-u.ac.jp

CC chemokine receptor (CCR) 5 and CXC chemokine receptor (CXCR)3 are expressed on T helper cell type 1 cells and have been implicated in their migration to sites of inflammation. Our preceding study demonstrated that a nonpeptide synthetic CCR5 antagonist, TAK-779 {N, N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6, 7-dihydro-5H-benzocyclohepten-8-yl]carbon-yl]amino]benzyl]-tetrahydro-2H-pyran4-aminium chloride, inhibits the development of experimentally induced arthritis by modulating the migration of CCR5+/CXCR3+ T cells to joints. The present study investigated the functional properties of TAK-779, including the effect of this antagonist on CXCR3 function. For this purpose, transfectants expressing mouse CCR5 (mCCR5) or mCXCR3 and expressing mCCR4 or mCXCR4 as controls were established by introducing each relevant gene into 2B4 T cells and were subjected to the following assays. First, the ligand binding to chemokine receptors was assayed by incubating transfectants with [125I]-labeled relevant ligand or with the unlabeled relevant ligand followed by staining with anti-ligand antibody. Second, chemokine-induced lymphocyte function-associated antigen-1 (LFA-1) activation was assayed by measuring the adhesion of cells to microculture plates coated with purified intercellular adhesion molecule-1. Third, chemokine-stimulated chemotaxis was assayed by observing the cell migration through transwells. In these assays, TAK-779 blocked the ligand binding as well as LFA-1 up-regulating and chemotactic function of mCXCR3 and mCCR5 but did not elicit a biologically significant inhibition of those functions of mCCR4 and mCXCR4. These observations indicate the unique target specificity of TAK-779 and explain why this antagonist efficiently blocks the migration of T cells expressing CCR5 and CXCR3 to sites of inflammation.

Key Words: chemokines • chemotaxis • CCR5 • CXCR3




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
D. Verzijl, S. Storelli, D. J. Scholten, L. Bosch, T. A. Reinhart, D. N. Streblow, C. P. Tensen, C. P. Fitzsimons, G. J. R. Zaman, J. E. Pease, et al.
Noncompetitive Antagonism and Inverse Agonism as Mechanism of Action of Nonpeptidergic Antagonists at Primate and Rodent CXCR3 Chemokine Receptors
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 544 - 555.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
Y. Suzaki, K. Hamada, T. Nomi, T. Ito, M. Sho, Y. Kai, Y. Nakajima, and H. Kimura
A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation
Eur. Respir. J., April 1, 2008; 31(4): 783 - 789.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Sohy, M. Parmentier, and J.-Y. Springael
Allosteric Transinhibition by Specific Antagonists in CCR2/CXCR4 Heterodimers
J. Biol. Chem., October 12, 2007; 282(41): 30062 - 30069.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Hatse, D. Huskens, K. Princen, K. Vermeire, G. J. Bridger, E. De Clercq, M. M. Rosenkilde, T. W. Schwartz, and D. Schols
Modest Human Immunodeficiency Virus Coreceptor Function of CXCR3 Is Strongly Enhanced by Mimicking the CXCR4 Ligand Binding Pocket in the CXCR3 Receptor
J. Virol., April 1, 2007; 81(7): 3632 - 3639.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
E. J.A. van Wanrooij, H. Happe, A. D. Hauer, P. de Vos, T. Imanishi, H. Fujiwara, T. J.C. van Berkel, and J. Kuiper
HIV Entry Inhibitor TAK-779 Attenuates Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2642 - 2647.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Gao, R. L. Wange, N. Zhang, J. J. Oppenheim, and O. M. Z. Howard
Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN
Blood, October 15, 2005; 106(8): 2619 - 2626.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
Y. Morimoto, Y. Bian, P. Gao, Y. Yashiro-Ohtani, X.-Y. Zhou, S. Ono, H. Nakahara, M. Kogo, T. Hamaoka, and H. Fujiwara
Induction of surface CCR4 and its functionality in mouse Th2 cells is regulated differently during Th2 development
J. Leukoc. Biol., September 1, 2005; 78(3): 753 - 761.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
H. Tokuyama, S. Ueha, M. Kurachi, K. Matsushima, F. Moriyasu, R. S. Blumberg, and K. Kakimi
The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis
Int. Immunol., August 1, 2005; 17(8): 1023 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. E. Heise, A. Pahuja, S. C. Hudson, M. S. Mistry, A. L. Putnam, M. M. Gross, P. A. Gottlieb, W. S. Wade, M. Kiankarimi, D. Schwarz, et al.
Pharmacological Characterization of CXC Chemokine Receptor 3 Ligands and a Small Molecule Antagonist
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1263 - 1271.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. Schroppel, N. Zhang, P. Chen, W. Zang, D. Chen, K. L. Hudkins, W. A. Kuziel, R. Sung, J. S. Bromberg, and B. Murphy
Differential Expression of Chemokines and Chemokine Receptors in Murine Islet Allografts: The Role of CCR2 and CCR5 Signaling Pathways
J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1853 - 1861.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Segerer, B. Banas, M. Wornle, H. Schmid, C. D. Cohen, M. Kretzler, M. Mack, E. Kiss, P. J. Nelson, D. Schlondorff, et al.
CXCR3 Is Involved in Tubulointerstitial Injury in Human Glomerulonephritis
Am. J. Pathol., February 1, 2004; 164(2): 635 - 649.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Society for Leukocyte Biology.